Knowledge on Allergic Inflammation - the Basis for Solving the Problem of Bronchial Asthma.

The manifestations of allergen-specific IgE-mediated reactions constitute the basis of allergic inflammation as universal specialized form of recognition of allergen entered the body and organization of response reaction in relation to this foreign agent. The stage of induction of special type of immune response by the body entered allergen is a decisive one in the chain of replaceable events terminated by external signs of allergy. This response results in the formation of allergic antibodies that belong to immunoglobulin E (IgE) which are fixed on inflammatory cells, "arming" them by specific mechanism of recognition of new body entering allergen.

Extracorporal Immunopharmacotherapy.

The methods of extracorporal immunopharmacotherapy may be attributed to cell engineering immunocorrection therapy and allows to apply regulatory immune cells and their short-distance mediators after pharmaceutical activation in vitro (extracorporally). The therapy implores: (1) in vitro drug-dependent activation of leukocytes obtained from patient's blood, and (2) withdrawal of the activatory drugs and reinfusion of activated leukocytes back to the patient. By doing this it is possible to perform drug treatment of the patient not in his body, but in vitro through stimulating only a part of his cells.

In vitro uptake of 5-hydroxytryptamine and dopamine by rat mast cells after exocytosis induced by antigen or compound 48/80.

Mast cells from the peritoneal and pleural cavities of actively sensitized rats were isolated and incubated with biogenic amines (5-hydroxytryptamine and dopamine) with or without pretreatment with specific antigen. An anaphylactic reaction resulting in the release of 20-25% of the histamine in the cells led to a slightly reduced amine uptake. At concentrations which induced histamine release comparable to that during the anaphylactic reaction compound 48/80 had a similar effect on the uptake of the two amines.